Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open Label Follow-Up Study of Liposomal Ciclosporin A in CLAD-BOS Post Lung Transplantation
2024-512448-41-00Phase 3Completed
- Sponsor
- Zambon
- Start
- Jul 2024
- Modality
- Small Molecules, Peptides, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of liposomal ciclosporin A in Bronchiolitis Obliterans Syndrome (BOS), sponsored by Zambon. Primary endpoints: Adverse events (AEs), Acute tolerability of investigational medicinal product after initial dosing and 16 more. Started Jul 2024; status: completed.
02
Drugs
liposomal ciclosporin A
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on 2024-512448-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512448-41-00.